Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, 9500 Euclid Avenue, S73, Cleveland, OH 44195, USA.
Expert Rev Anticancer Ther. 2011 Feb;11(2):161-3. doi: 10.1586/era.10.227.
A number of important studies were presented at the Society for Neuro-Oncology annual meeting in Montréal, Canada, on 18-21 November 2010. Cediranib as monotherapy or in combination with lomustine did not show increased efficacy when compared with lomustine alone in patients with recurrent glioblastoma (GBM). Addition of temozolomide (TMZ) or irinotecan (CPT) to bevacizumab (BEV) in patients with recurrent GBM was well tolerated, with similar efficacy to BEV alone. The addition of BEV to radiation and TMZ in newly diagnosed GBM improved progression-free survival but did not improve overall survival. TMZ alone may be a reasonable approach in elderly GBM patients with poor performance status. Two Phase II trials with sunitinib and vatalanib showed a hint of activity in patients with recurrent or progressive meningiomas.
在 2010 年 11 月 18 日至 21 日于加拿大蒙特利尔举行的神经肿瘤学年会上提交了一些重要的研究。西地尼布单药治疗或与洛莫司汀联合治疗在复发性胶质母细胞瘤（GBM）患者中并未显示比洛莫司汀单独治疗更有效。替莫唑胺（TMZ）或伊立替康（CPT）联合贝伐单抗（BEV）在复发性 GBM 患者中耐受性良好，与单独使用 BEV 的疗效相似。贝伐单抗联合放疗和 TMZ 用于新诊断的 GBM 可改善无进展生存期，但未改善总生存期。TMZ 单药治疗可能是体能状态差的老年 GBM 患者的合理治疗方法。两项舒尼替尼和凡德他尼的 II 期试验显示，在复发性或进展性脑膜瘤患者中具有一定的疗效。
